Moonwalk Biosciences

Moonwalk Biosciences is a private, pre-clinical stage biotech leveraging a proprietary platform that intersects comprehensive human genetic analysis with epigenetic profiling of adipose tissue to discover novel therapeutic targets. The company has pivoted its initial epigenetic editing focus towards developing adipose-targeted siRNA therapies for obesity, with multiple candidates showing preclinical efficacy. Backed by a seasoned leadership team with experience from companies like Amgen and academic pioneers like Feng Zhang, Moonwalk is positioned to address the significant unmet need in metabolic disease through a novel biology-driven approach.

Integrated discovery platform combining comprehensive human genetic analysis (GWAS mapping) with epigenetic profiling (whole-genome DNA methylation) of adipose tissue to identify and validate novel, causal therapeutic targets for metabolic disease.

Moonwalk competes in the crowded obesity therapeutics arena, dominated by incumbents like Novo Nordisk and Eli Lilly. Its differentiation lies in its novel target discovery platform and a direct adipose-tissue targeting approach, positioning it against other biotechs exploring alternative mechanisms (e.g., amylin, incretin combinations) and next-generation siRNA/oligonucleotide companies.